- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:46 | Analysts praise intismeran's landmark Phase III win, look to further data | ||
| 11:46 | Gossamer Bio announces $250m in funding to advance seralutinib | ||
| 11:46 | Johnson & Johnson's multiple myeloma treatment secures EC approval | ||
| Fr | Roche commits $750m to double Oregon-based US manufacturing capacity | ||
| Fr | Eli Lilly's weekly insulin jab Onswik set for NHS use if approved | ||
| Fr | WellSpan and Johns Hopkins renew partnership for advanced cancer care access | ||
| Fr | Charles River and MVC to develop enterovirus vaccine | ||
| Do | Regeneron's Pasatru wins FDA approval in ultra-rare 'stone man disease' | ||
| Do | Kynexis pockets €97m to advance cognition-focused schizophrenia drug | ||
| Do | FDA grants accelerated approval to Ultragenyx's Genglycos gene therapy | ||
| Do | SandboxAQ introduces AQPotency for virtual drug screening | ||
| Mi | BioMarin spends up to $490m for Alesta's bone disease candidate | ||
| Mi | Trump expected to nominate Heidi Overton as new FDA commissioner | ||
| Mi | Andelyn Biosciences to develop GM2 gangliosidosis therapy | ||
| Mi | BeOne Medicines and partners renew Brukinsa access programme for CLL | ||
| Di | LEO outlays $435m for rights to Tanabe's rare disease drug for sun-induced pain | ||
| Di | Faeth's PIKTOR plus paclitaxel combo gains FDA fast track status | ||
| Di | Fulcrum Therapeutics and Slate Medicines sign merger agreement | ||
| 17.08. | Moving at the speed of pharma digitalisation: driving ROI from AI and digital tools | ||
| 17.08. | Sandoz targets industry patent void with $322m Henlius deal | ||
| 17.08. | Lantheus Holdings' Alzheimer's radiodiagnostic secures FDA approval | ||
| 17.08. | EMA validates Pfizer and Valneva's Lyme disease vaccine | ||
| 17.08. | FDA grants fast track status to Phanes' spevatamig for advanced BTC | ||
| 14.08. | Immunology specialist Khartis Therapeutics emerges from stealth with $95m | ||
| 14.08. | BMS secures FDA accelerated approval for Zenbexus in multiple myeloma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.